TABLE 5.
Multivariate regression analysis.
| Variable | Skindex‐29 symptoms | Skindex‐29 emotions | Skindex‐29 functions | Skindex‐29 total | NF1‐AdQOL symptoms | NF1‐AdQOL emotions | NF1‐AdQOL functions | NF1‐AdQOL total | HADS anxiety | HADS depression | HADS total | DLQI | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | p‐value | p‐value | Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | Coefficient (95% CI) | p‐value | |
| Age (years) a | ||||||||||||||||||||||||
| 20–29 | 1.328 (−2.38–5.03) | 0.065 | −2.728 (−7.67–2.215) | 0.276 | −0.855 (−5.17 to 3.46) | 0.695 | −2.256 (−13.71 to 9.20) | 0.697 | −1.834 (−5.78 to 2.12) | 0.359 | −2.880 (−7.19 to 1.43) | 0.188 | −2.724 (−7.09 to 1.64) | 0.218 | −9.552 (−20.77 to 1.67) | 0.094 | −0.160 (−1.06 to 0.74) | 0.722 | 0.391 (−0.40 to 1.18) | 0.326 | 0.232 (−1.28 to 1.74) | 0.759 | −0.833 (−2.00 to 0.332) | 0.158 |
| 30–39 | ||||||||||||||||||||||||
| 40–49 | ||||||||||||||||||||||||
| 50–59 | ||||||||||||||||||||||||
| 60+ | ||||||||||||||||||||||||
| Gender | ||||||||||||||||||||||||
| Male | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | ||||||||||||
| Female | 11.722 (2.325–21.20) | 0.015 | 11.653 (−0.89 to 24.20) | 0.068 | 9.256 (1.71–20.22) | 0.097 | 32.63 (3.55–61.71) | 0.028 | 11.891 (2.00–21.78) | 0.019 | 13.461 (2.66–24.26) | 0.015 | 9.523 (−1.40 to 20.45) | 0.087 | 31.57 (3.25–59.90) | 0.029 | 2.469 (0.21–4.90) | 0.048 | 0.225 (−1.93 to 2.38) | 0.835 | 2.69 (−1.42–6.79) | 0.195 | 0.397 | 0.789 |
| Visibility a | ||||||||||||||||||||||||
| 1 | 9.195 (3.60–14.79) | 0.002 | 8.872 (1.40–16.34) | 0.020 | 9.599 (3.07–16.13) | 0.004 | 27.67 (10.35–44.98) | 0.002 | 7.832 (1.94–13.72) | 0.010 | 6.161 (−0.27 to 12.59) | 0.060 | 7.868 (1.36–14.38) | 0.018 | 19.55 (2.71–36.39) | 0.023 | 0.004 (−1.49 to 1.50) | 0.996 | 0.686 (−0.64 to 2.01) | 0.304 | 0.690 (−1.83 to 3.21) | 0.585 | 3.220 (1.32–5.12) | 0.001 |
| 2 | ||||||||||||||||||||||||
| 3 | ||||||||||||||||||||||||
| Itch | ||||||||||||||||||||||||
| No | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | ||||||||||||
| Yes | 14.232 (5.359–23.11) | 0.002 | 8.052 (−2.83 to 21.01) | 0.180 | 7.683 (−2.67 to 18.03) | 0.144 | 29.97 (2.51–57.42) | 0.033 | 11.605 (2.286–20.92) | 0.015 | 11.063 (0.89–21.24) | 0.033 | 9.571 (−0.73 to 19.87) | 0.068 | 35.52 (8.83–62.20) | 0.010 | 1.457 (−0.88 to 3.80) | 0.217 | 1.606 (−0.46–3.67) | 0.125 | 3.063 (−0.87 to 7.00) | 0.125 | 1.463 (−1.25 to 4.18) | 0.287 |
Abbreviations: CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; DLQI, Dermatology Life Quality Index; NF1‐AdQOL, Neurofibromatosis 1‐adult quality‐of‐life questionnaire.
a
Variable fitted as continuous variable in regression modeling. Unit of measurement is per 10 year increase for age, and per 1 unit increase for number of cutaneous neurofibromas, visibility and severity score.